论文部分内容阅读
应用火箭免疫电泳法测定57例Graves病治疗前后载脂蛋白A_1(APO A_1)和载脂蛋白B_(100)(APO B_(100))血清浓度,发现活动性甲状腺亢进时治疗前APO A_1 43.09±4.7/μmol/L,APO B_(100)0.762±0.177μmol/L,低于正常值(APO A_2 43.49±5.61μmol/L,APO B_(100) 1.147±0.22μmol/L);治疗后APO A_1和APO B_(100)血浓度上升,分别为46.4±4.7μmol/L和1.083±0.17μmol/L,与治疗前比较有统计学差异。治疗前APO A_1/APO B_(100)比值为2.84±0.52,治疗后比值下降为2.10±0.38(P<0.01),提示甲状腺功能亢进时,甲状腺激素对APO A_1和APO B_(100)代谢的影响。
The serum concentrations of apolipoprotein A_1 (APO A_1) and apolipoprotein B_ (100) (APO B_ (100)) in 57 patients with Graves’ disease before and after treatment were measured by rocket immunoelectrophoresis. It was found that APO A_1 43.09 ± APO B_ (100) 0.762 ± 0.177μmol / L, lower than normal value (APO A_2 43.49 ± 5.61μmol / L, APO B 100 (1.147 ± 0.22μmol / L) The blood concentration of APO B_ (100) increased 46.4 ± 4.7μmol / L and 1.083 ± 0.17μmol / L, respectively, with statistical difference before treatment. The ratio of APO A_1 / APO B_ (100) before treatment was 2.84 ± 0.52, and the ratio decreased to 2.10 ± 0.38 (P <0.01) after treatment, suggesting that the effect of thyroid hormones on APO A_1 and APO B_ (100) metabolism in hyperthyroidism .